Titia de Lange, Ph.D., Rockefeller University
Jerry W. Shay, Ph.D., UT Southwestern
Hilton Denver Inverness
200 Inverness Drive West
Englewood, CO 80112
Meeting #: Refer to your packet.
Hours: 8:00am – 8:00 pm EST M-F
International : 623-516-6140
As humans age, the ends of linear chromosomes, telomeres, become progressively shorter. Short telomeres elicit a DNA damage response that leads cells to stop dividing and undergo senescence or apoptosis. This process inhibits the outgrowth of cancer cells that have undergone an abnormally high number of cell divisions. However, rare cancer cells can activate a cellular reverse transcriptase, telomerase, to reconstitute functional telomeres. Telomerase is absent in most normal tissues but is detected in the great majority of clinically detectable cancers. Thus, while telomerase is not oncogenic per se, it is almost universally required to permit the indefinite growth that occurs as part of cancer progression. Therefore, the inhibition of telomerase is an attractive target for cancer therapeutics. There have been several approaches to targeting telomerase in cancer in the past but none have advanced to late stage clinical trials. Thus, it is timely to review the progress and future directions for targeting telomerase in this Forbeck conference. Topics will include a discussion on why progress has been slow and how going forward this may change using new approaches. There will discussions on human genetic disorders affecting telomeres, alternatives to telomerase in a subset of tumors and the role of senescence as an initial brake preventing premalignant cells from progressing to advanced cancers.
|Mary Armanios, MD||Johns Hopkins Medical Institute|
|Stephen Artandi, MD, PhD||Stanford University|
|Rene Bernards, PhD||Netherlands Cancer Institute|
|Allison Bertuch, MD, PhD||Texas Children's Hospital|
|Simon Boulton, PhD||Francis Crick Institute UK|
|Rochelle Buffenstein, PhD||Calico Lab|
|Carla Daniela Robles-Espinoza, PhD||International Laboratory for Human Genome Research|
|Titia De Lange, PhD||Rockefeller University|
|Roger Greenberg, MD, PhD||Univeristy of Pennsylvania|
|Dirk Hockenmeyer, PhD||University of California, Berkeley|
|Marcin Imielinski, MD, PhD||Weill Cornell Medicine|
|Jan Karlseder, PH.D.||The Salk Institute|
|Joachim Lingner||Ecole Polytech Federale de Lausanne|
|Vicki Lundbald||The Salk Institute|
|Roderick O'Sullivan, PhD||University of Pittsburgth Medical Center|
|Sharon Savage, MD||National Institutes of Health|
|Agnel Sfeir, PhD||New York University|
|Jerry Shay, PhD||UT Southwestern|
|Floris Barthel, MD||The Jackson Laboratory for Genomic Medicine|
|Marta Markiwica-Potoczny, PhD||University of Pittsburgh|
|Enzo Tedone, PhD||UT Southwestern|
|Tianpeng Zhang, PhD||University of Pennsylvania|
Denver International Airport (DEN) is the preferred airport as it is only 30 minutes from the meeting location.
The abstracts should be only one or two paragraphs outlining the theme of your presentation and should reflect the objective and spirit of the meeting (see above). Abstracts will be circulated about one week before the meeting. The meeting organizer will start requesting them a month before the meeting.
For more than 30 years, the Forbeck Foundation has proven to be an excellent steward of donor funds and has remained focused on executing its mission. Interested in sponsoring this Forum? Contact us today for more information!